ATE446767T1 - Gm-csf zur behandlung von morbus crohn - Google Patents

Gm-csf zur behandlung von morbus crohn

Info

Publication number
ATE446767T1
ATE446767T1 AT00913421T AT00913421T ATE446767T1 AT E446767 T1 ATE446767 T1 AT E446767T1 AT 00913421 T AT00913421 T AT 00913421T AT 00913421 T AT00913421 T AT 00913421T AT E446767 T1 ATE446767 T1 AT E446767T1
Authority
AT
Austria
Prior art keywords
csf
disease
crohn
treatment
factors
Prior art date
Application number
AT00913421T
Other languages
German (de)
English (en)
Inventor
Brian Dieckgraefe
Joshua Korzenick
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE446767T1 publication Critical patent/ATE446767T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Studio Devices (AREA)
  • Silicon Compounds (AREA)
  • Treatment Of Sludge (AREA)
AT00913421T 1999-02-12 2000-02-11 Gm-csf zur behandlung von morbus crohn ATE446767T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11984299P 1999-02-12 1999-02-12
PCT/US2000/003407 WO2000047195A1 (en) 1999-02-12 2000-02-11 Stimulating neutrophil function to treat inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE446767T1 true ATE446767T1 (de) 2009-11-15

Family

ID=22386711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913421T ATE446767T1 (de) 1999-02-12 2000-02-11 Gm-csf zur behandlung von morbus crohn

Country Status (7)

Country Link
EP (1) EP1150666B1 (enExample)
JP (2) JP2002536404A (enExample)
AT (1) ATE446767T1 (enExample)
AU (1) AU764681C (enExample)
CA (1) CA2367575A1 (enExample)
DE (1) DE60043216D1 (enExample)
WO (1) WO2000047195A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
WO2004100972A1 (ja) * 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. 組織破壊を伴う疾患の予防及び／または治療剤
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
WO2007134907A2 (en) * 2006-05-18 2007-11-29 Bayer Schering Pharma Aktiengesellschaft Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
DE3584089D1 (de) * 1984-07-06 1991-10-17 Sandoz Ag Herstellung und reinigung von lymphokinen.
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
EP0383764B1 (en) * 1987-06-25 1995-04-12 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
WO1995009622A1 (en) * 1993-10-06 1995-04-13 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5733915A (en) * 1995-03-30 1998-03-31 Glaxo Wellcome Inc. Use of azathioprine to treat crohn's disease
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
CA2285923C (en) * 1997-04-01 2013-03-12 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
DE19835080A1 (de) * 1998-07-27 2000-02-03 Doecke Wolf Dietrich Mittel zur Behandlung des Krankheitsbildes Morbus Crohn

Also Published As

Publication number Publication date
AU3487100A (en) 2000-08-29
WO2000047195A1 (en) 2000-08-17
JP2005225890A (ja) 2005-08-25
JP2002536404A (ja) 2002-10-29
EP1150666B1 (en) 2009-10-28
AU764681B2 (en) 2003-08-28
EP1150666A1 (en) 2001-11-07
AU764681C (en) 2005-07-07
CA2367575A1 (en) 2000-08-17
DE60043216D1 (de) 2009-12-10
EP1150666A4 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE302003T1 (de) Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion
PT932411E (pt) Composicoes contendo moleculas imunogenicas e factor estimulante de colonias de macrofagos- granulocitos como adjuvante
ATE232396T1 (de) Oxydiertes thymosin beta 4
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
IL99778A0 (en) Compositions for the treatment of cell proliferation disorders
ATE446767T1 (de) Gm-csf zur behandlung von morbus crohn
ATE81467T1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
ATE81462T1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
ES469908A1 (es) Procedimiento de utilizacion de salinomicina.
Shapira et al. P083 Simultaneous haploidentically mismatched stem cell transplantation from multi-donors (MDT) in humans offers better engraftment as compared to single donor
UA34283A (uk) Спосіб діагностики порушень імунологічного статусу у людини та тварин
UA29506C2 (uk) Лікувально-косметичний засіб "фіто-пелоїд"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties